Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zoledronic Acid Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 10/20 | 0.96 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.93 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.93 |
| ▸ | CA12 | O43570 | 1/20 | 0.93 |
| ▸ | CA2 | P00918 | 1/20 | 0.93 |
| ▸ | LMNA | P02545 | 1/20 | 0.93 |
| ▸ | MMP2 | P08253 | 1/20 | 0.93 |
| ▸ | MMP9 | P14780 | 1/20 | 0.93 |
| ▸ | MMP8 | P22894 | 1/20 | 0.93 |
| ▸ | MMP14 | P50281 | 1/20 | 0.93 |
| ▸ | CA9 | Q16790 | 1/20 | 0.93 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zoledronic Acid Anhydrous SCHEMBL1586366 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL19054 | 0.98 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160625 | 0.96 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL435847 | 0.96 | FDPS (1.00) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL22534391 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL515095 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160616 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL3180138 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL1160460 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 | |
| Zoledronic Acid Anhydrous SCHEMBL14603422 | 0.96 | FDPS (0.96) | FDPSGGPS1BTN3A1CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-208541609-U | A kind of inner fixing device for osteoporotic fracture treatment | 上海交通大学医学院附属第九人民医院 | 2019-02-26 | — | — | CN | disclosed |
| CN-107551329-A | A kind of inner fixing device treated for osteoporotic fracture and preparation method thereof | 上海交通大学医学院附属第九人民医院 | 2018-01-09 | — | — | CN | disclosed |
| WO-2010111627-A1 | IMPLANTABLE FORMULATIONS OF BISPHOSPHONIC ACIDS | PSIVIDA US, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100247607-A1 | IMPLANTABLE FORMULATIONS OF BISPHOSPHONIC ACIDS | PSIVIDA US, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7687636-B2 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2010-03-30 | — | — | US | disclosed |
| US-7589211-B2 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2009-09-15 | — | — | US | disclosed |
| US-7582768-B2 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2009-09-01 | — | — | US | disclosed |
| EP-1567533-B1 | ZOLEDRONIC ACID CRYSTAL FORMS, ZOLEDRONATE SODIUM SALT CRYSTAL FORMS, AMORPHOUS ZOLEDRONATE SODIUM SALT, AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMA (IL) | 2009-03-11 | — | — | EP | disclosed |
| US-7435827-B2 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2008-10-14 | — | — | US | disclosed |
| US-20070027323-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-02-01 | — | — | US | disclosed |
| US-20070021617-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021619-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021618-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021389-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| EP-1612212-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | Teva Pharmaceutical Industries Ltd (IL) | 2006-01-04 | — | — | EP | disclosed |
| EP-1567533-A2 | ZOLEDRONIC ACID CRYSTAL FORMS, ZOLEDRONATE SODIUM SALT CRYSTAL FORMS, AMORPHOUS ZOLEDRONATE SODIUM SALT, AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-08-31 | — | — | EP | disclosed |
| US-20050054616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | TEVA PHARMACEUTICALS USA, INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2005005447-A2 | ZOLEDRONIC ACID CRYSTAL FORMS, ZOLEDRONATE SODIUM SALT CRYSTAL FORMS, AMORPHOUS ZOLEDRONATE SODIUM SALT, AND PROCESSES FOR THEIR PREPARATION | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | SOST, FGF23, PTH1R | FDPS 905/4885GGPS1 588/4885BTN3A1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.